• Biophytis moved to implement a Hong Kong joint venture, Biophytis Biopharmaceutical Holding LTD, created June 2, 2026.
• Planned contribution includes BIO101 patents in China, Japan, South Korea, paired with a license deal covering those markets.
• Joint venture to pay single-digit royalties on future sales under the licensing agreement.
• Asian partners to fund an initial USD 3 million tranche, part of commitments up to USD 20 million, including USD 10 million in year one.
• Funding aimed at supporting the SARA-31 multi-regional Phase 3 sarcopenia trial through market authorization in China and the EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-101231), on August 26, 2026, and is solely responsible for the information contained therein.